Has Geron Undersold Itself To Janssen?
Kanak Kanti De • 252 Comments
Kanak Kanti De • 252 Comments
Thu, Feb. 25, 7:27 PM
- Geron (GERN -3%) is up 3.1% in after-hours trading following an in-line loss for its fourth quarter earnings on $220K in revenue.
- In the full year, the company eked out a profit of $46,000 vs. 2014's net loss of $35.7M. Revenues came to $36.4M, including full recognition of a $35M upfront payment from Janssen received in December 2014.
- Geron said the FDA granted orphan drug designation to imetelstat for the treatment of MF and for the treatment of MDS, and that the European Medicine Agency granted orphan drug designation to imetelstat for the treatment of MF.
- R&D expenses for 2015 were $17.8M vs. the prior year's $20.7M, mainly due to organizational resizing and lower costs to make imetelstat. G&A costs were $17.8M.
Dec. 7, 2015, 9:19 AM| Dec. 7, 2015, 9:19 AM | 714 Comments
Nov. 30, 2015, 12:49 PM
Nov. 25, 2015, 5:38 PM
Nov. 6, 2015, 9:29 AM
Sep. 4, 2015, 12:39 PM
- Thinly traded nano cap KaloBios Pharmaceuticals (KBIO +43.9%) jumps again in early trading on robust volume. Shares have more than doubled over the past two trading sessions.
- A possible driver of the bullish action may be Geron's (GERN -3.5%) interest in acquiring an early-stage oncology asset via licensing or outright purchase of a company. In the company's Q4 earnings call in March, CEO Chip Scarlett said the due diligence process to assess potential candidates was underway.
- Kalabios' two lead product candidates are KB004, a monoclonal antibody currently in Stage 2 development for myelofibrosis or myelodysplastic syndrome and KB003, a monoclonal antibody in Phase 1 development for chronic myelomonocytic leukemia.
Sep. 3, 2015, 9:12 AM
Sep. 2, 2015, 6:04 PM
- Geron (NASDAQ:GERN) +20.4% AH on news that the New England Journal of Medicine would publish two papers showing positive results for GERN's flagship drug imetelstat, an inhibitor of the telomerase cancer cell enzyme.
- In two mid-stage clinical trials, GERN said the use of imetelstat suggested it works against malignant cells that cause essential thrombocythemia, a disease in which the body produces too many blood platelets, and against myelofibrosis, a bone marrow disease that disrupts the body's production of blood cells.
Mar. 10, 2015, 3:51 PM
- Traders spread their love beyond the rumored acquisition target-stoked up move of Acadia Pharmaceuticals (ACAD +17.7%) to Geron (GERN +12.3%). Shares are up on a whopping 24M shares. Speculators are betting that Geron will be taken out, possibly by Johnson & Johnson (JNJ -0.8%), after the latter was outbid by AbbVie (ABBV +0.9%) for Pharmacyclics (PCYC).
- Previously: Geron gets boost from AbbVie-Pharmacyclics deal (March 5)
- Previously: Acadia Pharma now +17.7% as it cancels out of another conference (March 10)
Mar. 10, 2015, 12:45 PM
Mar. 5, 2015, 12:45 PM
Mar. 5, 2015, 12:15 PM
- Small cap Geron (GERN +17.8%) jumps on a 3x surge in volume as traders take positions speculating on the potential for a move by imetelstat collaboration partner and exclusive licensee Johnson & Johnson (JNJ +0.8%) after it was apparently outbid by AbbVie (ABBV -3.5%) for Pharmacyclics (PCYC +10.5%).
- SA Contributor Stock Doctor recently published an article on why Geron may be worth a close look.
- Previously: Geron wins deal to develop blood disorder drug, could get $935M (Nov. 13, 2014)
Feb. 23, 2015, 9:14 AM
Nov. 24, 2014, 9:12 AM
Nov. 21, 2014, 12:46 PM
Nov. 21, 2014, 12:01 PM
- Geron Corp. (GERN +12%) climbs again today on double normal volume. Shares are up almost 60% since its imetelstat development deal with Johnson & Johnson unit Janssen Biotech was announced on November 13.
- Previously: Geron wins deal to develop blood disorder drug, could get $935M
Geron Corp. discovers and develops therapeutic products for cancer. It is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Geron was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo... More
Country: United States